<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical use of local anesthetics in anesthesia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical use of local anesthetics in anesthesia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical use of local anesthetics in anesthesia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura Lahaye, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Coleman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maniker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2729256986"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Local anesthetics (LAs) are used to block transmission of impulses in nerve fibers, to reduce or eliminate sensation. LAs may be used for neuraxial analgesia and anesthesia, peripheral nerve blocks, subcutaneous and tissue infiltration, and topical anesthesia. This topic will discuss the mechanism of action of LAs, the properties that distinguish LAs and determine their effects, and the ways in which LAs are used in anesthesia.</p><p>The doses and effects of LAs used for specific regional anesthesia techniques are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105456.html" rel="external">"Spinal anesthesia: Technique", section on 'Local anesthetics'</a> and  <a class="medical medical_review" href="/z/d/html/89518.html" rel="external">"Epidural and combined spinal-epidural anesthesia: Techniques", section on 'Local anesthetics'</a> and  <a class="medical medical_review" href="/z/d/html/397.html" rel="external">"Overview of peripheral nerve blocks", section on 'Local anesthetics'</a>.)</p><p class="headingAnchor" id="H1541472085"><span class="h2">Mechanism of action of local anesthetics</span><span class="headingEndMark"> — </span>LAs reversibly inhibit nerve transmission by binding voltage-gated sodium channels (Na<sub>v</sub>) in the nerve plasma membrane. Na<sub>v</sub> channels are integral membrane proteins, anchored in the plasma membrane. When LAs bind the sodium channel, they render it impermeable to Na, which prevents action potential initiation and propagation [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Anatomy and physiology'</a>.)</p><p class="headingAnchor" id="H3639053136"><span class="h2">Basic structure/classes</span><span class="headingEndMark"> — </span>As noted above, the commonly used LAs have similar structural characteristics and (with the sole exception of articaine) consist of a lipophilic aromatic ring and a hydrophilic tertiary amine. These two moieties are linked by either a carboxylic ester (-COO-) or amide (-NCO-) bond. This linkage determines whether a LA is designated an amino ester or amino amide. Commonly used ester LAs include <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a>, procaine, and <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a>. The commonly used amide LAs include <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>, <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a>, <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a>, and outside the United States, levobupivacaine. Articaine is an amide LA used primarily in dentistry.</p><p>LAs are weak bases that exist in solution in both charged and uncharged forms. All clinically-used LAs share certain structural features. The aromatic (benzene) ring leads to greater lipid solubility. Lipid solubility declines (and aqueous solubility increases) when the amine nitrogen (at the end of the molecule opposite to the aromatic ring) is protonated (quaternary). When this amine nitrogen is in a tertiary form, it is uncharged and more lipid soluble. The uncharged, more lipophilic form more readily permeates nerve membranes, whereas the charged, more water soluble form binds with greater affinity for the sodium channel. LAs (save for <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a>) are supplied by the manufacturer in quaternary form as hydrochloride salts. The proportion of charged and uncharged forms (and, as a consequence, the speed with which they permeate the plasma membrane and produce their clinical effects) is determined by the pKa of the drug, and in vivo, by tissue pH.</p><p>The mechanism of metabolism, and potential for allergic reaction differ between the two classes of LAs. (See <a class="local">'Metabolism of local anesthetics'</a> below and <a class="local">'Allergic reactions'</a> below and  <a class="medical medical_review" href="/z/d/html/2084.html" rel="external">"Allergic reactions to local anesthetics"</a>.)</p><p class="headingAnchor" id="H3679219362"><span class="h1">LOCAL ANESTHETIC PHARMACODYNAMICS</span><span class="headingEndMark"> — </span>The potency, speed of onset, duration of action, and differential sensory versus motor block in isolated nerves are determined by the physicochemical characteristics of the LA. In vivo, these characteristics are also affected by the site of injection, drug concentration and volume, technical aspects of nerve block, vasodilatory properties of the drug, and tissue conditions (eg, pH).</p><p class="headingAnchor" id="H3917335018"><span class="h2">Potency</span><span class="headingEndMark"> — </span>Potency of an LA is strongly associated with lipid solubility, as LAs with greater lipid solubility are able to permeate nerve membranes more readily than less lipid soluble LAs [<a href="#rid2">2</a>]. As an example, <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> is more lipid soluble than <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, and is also more potent, such that 2% lidocaine would be used for epidural anesthesia, versus 0.5% bupivacaine. LA molecules with greater molecular weight more readily permeate nerve membranes and have a greater affinity for binding the Na channel than smaller LA molecules. As molecular weight increases, so generally does lipid solubility.</p><p>In addition, the larger, more lipid-soluble LAs are more highly protein bound.</p><p class="headingAnchor" id="H2796854636"><span class="h2">Speed of onset</span><span class="headingEndMark"> — </span>The speed of onset of LA conduction block depends on the physicochemical properties of the specific drug, the concentration of the solution, and the site of injection. In general, the time to<strong> </strong>onset increases with increasing lipid solubility. All other factors being equal, a more rapid onset is expected when the solution contains a greater fraction of nonionized molecules (eg, at increased pH). When the dose is held constant, increasing the concentration of the injected LA has been demonstrated to decrease the time to onset of peripheral nerve block [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Site of injection </strong>–<strong> </strong>Onset of anesthesia is almost immediate with subcutaneous or tissue infiltration with any LA. Onset is also very rapid (ie, within several minutes) with intrathecal injection for spinal anesthesia, because the drug is deposited close to the nerve roots and spinal cord, without having to diffuse through tissue. In contrast, onset of brachial plexus block is prolonged (ie, 20 to 30 minutes), because the drug may be deposited at some distance from the target nerves, and must diffuse through tissues. Ultrasound guidance allows injection of LAs close to target nerves for individual nerve blocks, and may speed onset [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkalinization </strong>–<strong> </strong>When speed of onset is of particular importance for peripheral nerve block or epidural anesthesia, some LA solutions may be alkalinized with the addition of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, thereby increasing the fraction of nonionized LA molecules. This strategy is most successfully employed with LA solutions premixed with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> at the factory. These solutions are prepared in a considerably more acidic solution than "plain" LAs to increase the shelf life of the epinephrine [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">As an example, 1 and 2% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> with 1:100,000 <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> have a pH of approximately 4. The volume of 8.4% <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> required to raise the pH to physiologic range is 1 mL per 10 mL of LA. At this ratio, the lidocaine solution is unlikely to precipitate, which is of concern at higher pH. Plain solutions are packaged at a pH of 6 and further alkalinization does not confer any advantage in onset time [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Alkalinization is generally not used for solutions of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> or <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a>, as onset times are not consistently shortened, and other LAs would typically be chosen if rapid onset is desirable. Bupivacaine can easily precipitate when alkalinized, and a smaller amount of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> should be added if it is used (ie, 0.1 mL of bicarbonate per 10 mL of bupivacaine). (See  <a class="medical medical_review" href="/z/d/html/89518.html" rel="external">"Epidural and combined spinal-epidural anesthesia: Techniques", section on 'Sodium bicarbonate'</a>.)</p><p></p><p class="bulletIndent1">Alkalinization of LA solutions can also be used to decrease the pain associated with subcutaneous or tissue infiltration. (See  <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Methods to decrease injection pain'</a>.)</p><p></p><p class="headingAnchor" id="H3626018083"><span class="h2">Duration of action</span><span class="headingEndMark"> — </span>The duration of action of LAs varies widely, and in the isolated nerve is associated with the degree of lipid solubility, and the chemical structure of the drug. <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">Chloroprocaine</a> and procaine are short acting LAs, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a>, and <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">prilocaine</a> result in moderate duration of action, and <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>, <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a>, levobupivacaine, <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a>, and etidocaine are the longest acting of the commonly used LAs  (<a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">table 1</a>). The more potent LAs are the longest-persisting, most likely because their increased lipid solubility leads to slower uptake and removal by the blood stream.</p><p>In vivo, the duration of action of a specific LA varies widely, and is affected by other factors, including the intrinsic vascular effects of the specific drug, concentration of the LA, protein binding, metabolism of the drug, local tissue conditions, and the site of injection. As an example, spinal anesthesia with <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> resolves over approximately 2.5 hours  (<a class="graphic graphic_table graphicRef108422" href="/z/d/graphic/108422.html" rel="external">table 2</a>), whereas single injection brachial plexus block with bupivacaine can result in 5 to 15 hours of anesthesia, and up to 30 hours of analgesia  (<a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2368018785"><span class="h2">Differential blockade</span><span class="headingEndMark"> — </span>Nerve fiber characteristics that lead to differing susceptibility to LA conduction block include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For nerve fibers with a relatively small diameter, a lower concentration of LA is required to achieve blockade than for a larger diameter fiber of the same type [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A shorter length of exposure to LA is required to block smaller fibers [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myelinated fibers require exposure of three or more adjacent nodes of Ranvier to LA for successful block [<a href="#rid10">10</a>].</p><p></p><p>On the other hand, in general and based on animal studies, unmyelinated (C) fibers are more resistant to inhibition by LAs than many myelinated fibers even though myelinated fibers are larger [<a href="#rid11">11</a>].</p><p>Nerve blocks in the clinical setting typically impair sympathetic function most expeditiously, followed by loss of sensation to sharp pain, temperature, and then pressure. Motor function is typically lost last. As a consequence, after LA injection for a nerve block, sympathectomy with vasodilation is often the first marker of a successful block. As the block develops, painful sensations will be blocked before motor function is lost. Differences in onset between motor and sensory function are more apparent with some LAs (eg, <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> and <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a>) than with others (<a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a> or <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>). Spinal and epidural anesthesia will demonstrate zones of differential block at the uppermost dermatomes of block, where one can observe clearly more widespread inhibition of cold sensation versus pinprick sensation. (See <a class="local">'Spinal anesthesia'</a> below and <a class="local">'Epidural anesthesia'</a> below.)</p><p class="headingAnchor" id="H1106232256"><span class="h1">SERUM CONCENTRATION OF LOCAL ANESTHETICS</span><span class="headingEndMark"> — </span>Serum levels of LA can be the result of systemic absorption from block sites, or accidental intravascular injection. High serum levels can cause both minor signs and symptoms of LA systemic toxicity (LAST; eg, perioral numbness, metallic taste, mental status changes or anxiety, visual changes), or major LAST events (ie, seizures or cardiac arrest) [<a href="#rid12">12</a>].</p><p>LAs bind to plasma proteins, primarily to alpha1-acid glycoprotein and secondarily to albumin. The fraction of protein binding of LA molecules in the blood increases with the drug's lipid solubility. Importantly, acidosis decreases the degree of protein binding by increasing the fraction of protonated LA molecules, thereby enhancing the unbound fraction of the drug. This is one of the reasons that acidosis must be avoided during treatment of LAST, since the unbound drug produces systemic toxic effects. (See  <a class="medical medical_review" href="/z/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity", section on 'Management of LAST'</a>.)</p><p>The factors that determine systemic absorption and the risk of LAST, preventive measures, and treatment of LAST are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity"</a>.)</p><p class="headingAnchor" id="H1905944939"><span class="h2">Maximum allowable doses</span><span class="headingEndMark"> — </span>Maximum allowable doses of LA that appear in various publications are at best rough guides, and are not consistent across publications. They are not evidence based, and don't take into account the site or technique of LA administration, or patient factors that increase the risk of toxicity. Systemic toxicity may occur with doses within the recommended ranges, while doses in excess of the recommended maximums have been administered without toxicity. Nonetheless, published maximum recommended doses can be used as a starting point for deciding on a dose. The total dose of LA administered should be the lowest dose that is required for the desired extent and duration of block  (<a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity", section on 'Local anesthetic dose'</a>.)</p><p class="headingAnchor" id="H4256836461"><span class="h2">Metabolism of local anesthetics</span><span class="headingEndMark"> — </span>The metabolism of a LA is dictated by its chemical structure and differs between ester and amide classes.</p><p class="bulletIndent1"><span class="glyph">●</span>Ester LAs are hydrolyzed by plasma cholinesterase, and conditions in which cholinesterase activity is reduced (ie, atypical pseudocholinesterase or pseudocholinesterase deficiency) theoretically predispose to reduced metabolism. In one case report, a patient who was ultimately found to have atypical pseudocholinesterase exhibited markedly prolonged epidural anesthesia with <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a>, as well as prolonged paralysis with <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>, which is also metabolized by pseudocholinesterase [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Pseudocholinesterase levels are reduced by approximately 24 percent during pregnancy, and by 33 percent on the third postpartum day, and return to normal over the first two to six weeks after delivery [<a href="#rid14">14</a>]. The clinical relevance of this decrease is unclear [<a href="#rid15">15</a>], and pregnant patients do not usually have a prolonged response to <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The amide LAs undergo N-dealkylation by hepatic enzymes. Conditions that reduce enzymatic function or hepatic blood flow (eg, renal, hepatic, or cardiac disease) may prolong LA clearance, and therefore increase the duration of block and serum levels. In such patients, doses of LA should be reduced for repeat or continuous administration.</p><p></p><p class="headingAnchor" id="H4156541190"><span class="h1">ALLERGIC REACTIONS</span><span class="headingEndMark"> — </span>Most idiosyncratic reactions to LAs are nonallergic in nature, but may be labelled as allergy. Symptoms of absorption or inadvertent injection of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> or LA, vasovagal reactions, or anxiety related symptoms can all mimic allergy. It has long been stated that allergic reactions are more common with LAs (such as procaine and <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a>) that are metabolized to P-aminobenzoic acid (PABA), but formal studies to confirm such assertions are lacking. Allergic contact dermatitis and delayed swelling at the site of LA administration are well established, and are more common with the ester group of LAs. Type 1, immediate hypersensitivity reactions, which can include anaphylaxis, are rare. Data implicating LAs are limited to case reports, which mostly involve reactions to amide LAs. The incidence, diagnosis, and management of allergy to LAs are discussed separately. An algorithm for preprocedural evaluation of patients who report a history LA allergy is provided  (<a class="graphic graphic_algorithm graphicRef117594" href="/z/d/graphic/117594.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2084.html" rel="external">"Allergic reactions to local anesthetics"</a> and  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>.)</p><p class="headingAnchor" id="H925461903"><span class="h1">NEUROTOXICITY OF LOCAL ANESTHETICS</span><span class="headingEndMark"> — </span>While all LAs have been shown to cause neurotoxicity in vitro at clinically relevant concentrations, the relevance of these findings to clinical practice is unclear. In general, the degree of toxicity is correlated with the concentration. Nevertheless, certain LAs used in particular clinical settings demonstrate a much higher degree of toxicity than others [<a href="#rid16">16</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lidocaine</strong><strong> </strong>–<strong> </strong>Reports of subarachnoid injection of 5% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> in glucose solution leading to transient neurologic symptoms (TNS; common) or permanent neurologic impairment (very rare) have greatly reduced the use of this solution for ambulatory spinal anesthesia in patients who will undergo surgery in the lithotomy position [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">Transient neurologic symptoms (TNS) are a constellation of non-permanent symptoms including back pain with radiation to buttocks or legs following spinal anesthesia. The reported incidence of TNS with spinal <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> varies from 14 percent to 37 percent [<a href="#rid17">17-19</a>], and is increased with lithotomy positioning, knee arthroscopy, and ambulatory procedures [<a href="#rid20">20</a>]. <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">Bupivacaine</a>, <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a>, <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a>, <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a>, and <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a> are associated with a lower incidence of TNS than lidocaine [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Subarachnoid 5% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> with dextrose administered via a spinal catheter has been implicated in rare cases of permanent neurologic injury, including cauda equina syndrome, with perineal sensory loss, varying degrees of urinary and/or fecal incontinence, and lower extremity motor weakness [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>2-Chloroprocaine</strong> – <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">Chloroprocaine</a> fell out of favor for use for epidural and spinal anesthesia following reports of prolonged sensory and motor block and subsequent adhesive arachnoiditis with the accidental spinal administration of large doses [<a href="#rid23">23-25</a>]. Use of a formulation containing a sodium metabisulfite preservative at an acidic pH may have contributed. Newer preservative-free preparations have not demonstrated similar toxicity. Indeed, the preservative-free form is now commonly used for brief spinal anesthetics in ambulatory patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mepivacaine</strong><strong> </strong>–<strong> </strong>The reported incidence of TNS after spinal anesthesia with <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a> likely depends on the concentration used. Based on mostly small studies, the reported incidence of TNS after spinal anesthesia with 4% mepivacaine is 30 to 37 percent [<a href="#rid26">26,27</a>], versus 0 to 7.5 percent with the reduced concentrations (1.5% to 2% mepivacaine) commonly used in most centers [<a href="#rid28">28-30</a>].</p><p></p><p class="headingAnchor" id="H2847659715"><span class="h1">COMBINATIONS OF LOCAL ANESTHETICS</span><span class="headingEndMark"> — </span>The combination of a short (intermediate) acting and long acting LA is often used in clinical practice to speed block onset while maintaining duration of blockade. Results are mixed in clinical trials with some studies demonstrating no difference in onset with a combination versus either anesthetic alone [<a href="#rid31">31</a>] while others report faster speed of onset with the combination than with the long acting agent alone [<a href="#rid32">32</a>]. In general, the combination of LAs may provide a block onset and duration that is intermediate between the longer and shorter acting agents [<a href="#rid31">31,32</a>].</p><p><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> may be mixed with aqueous <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> (as long as the bupivacaine dose is ≤50 percent of the liposomal bupivacaine dose) to speed the onset of block, but should not be mixed with other LAs. Restrictions on the combination of liposomal bupivacaine with other LAs are discussed below. (See <a class="local">'Sustained release bupivacaine'</a> below.)</p><p class="headingAnchor" id="H4105662087"><span class="h1">CLINICAL USES</span></p><p class="headingAnchor" id="H3362616465"><span class="h2">Neuraxial anesthesia</span></p><p class="headingAnchor" id="H2507934929"><span class="h3">Spinal anesthesia</span><span class="headingEndMark"> — </span>For single-shot spinal anesthesia, LAs and adjuvant medications must be chosen to achieve the required spinal level and duration of anesthesia. The most important determinants of the extent of sensory block (ie, dermatomal spread) are the baricity and (with hypobaric and hyperbaric solutions) the patient's position after injection of the anesthetic solution  (<a class="graphic graphic_table graphicRef108422" href="/z/d/graphic/108422.html" rel="external">table 2</a>). Increased LA dose increases the duration and the likelihood of a successful block. Baricity and other aspects of the choice of local anesthetics for spinal anesthesia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105456.html" rel="external">"Spinal anesthesia: Technique", section on 'Choice of spinal drugs'</a>.)</p><p class="headingAnchor" id="H1258712253"><span class="h3">Epidural anesthesia</span><span class="headingEndMark"> — </span>Multiple variables affect the dermatomal spread and duration of epidural anesthesia. The volume and total LA dose are the two most important drug related factors that influence the dermatomal extent and density of block. The concentrations of commonly used LAs, onset times, duration of action, block height, and recommended top up intervals are shown in tables  (<a class="graphic graphic_table graphicRef113983" href="/z/d/graphic/113983.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef113031" href="/z/d/graphic/113031.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/89518.html" rel="external">"Epidural and combined spinal-epidural anesthesia: Techniques", section on 'Choice of epidural drugs'</a>.)</p><p class="headingAnchor" id="H203606093"><span class="h2">Peripheral nerve block</span><span class="headingEndMark"> — </span>For peripheral nerve block, the LA and its volume and concentration are chosen according to the goal of the block (ie, surgical anesthesia and/or postoperative analgesia), degree of motor block, toxicity, and the desired duration of the block  (<a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">table 1</a>).<strong> </strong>These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/397.html" rel="external">"Overview of peripheral nerve blocks", section on 'Drugs'</a> and  <a class="medical medical_review" href="/z/d/html/100069.html" rel="external">"Upper extremity nerve blocks: Techniques", section on 'Drug choices'</a>.)</p><p class="headingAnchor" id="H4207812898"><span class="h2">Intravenous regional anesthesia</span><span class="headingEndMark"> — </span>In the United States, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> is used most commonly for intravenous regional anesthesia (IVRA). (See  <a class="medical medical_review" href="/z/d/html/100069.html" rel="external">"Upper extremity nerve blocks: Techniques", section on 'Intravenous regional anesthesia (Bier block)'</a>.)</p><p><a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">Prilocaine</a> is not available for intravenous use in the United States, but is used commonly for IVRA elsewhere. Prilocaine is less likely to cause central nervous system side effects with tourniquet deflation than <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> [<a href="#rid33">33</a>], but its application for regional anesthetics requiring larger doses (eg, epidural) is limited by its tendency to cause methemoglobinemia. The development of methemoglobinemia is a dose-dependent phenomenon and a consequence of the metabolism of prilocaine to the intermediate ortho-toluidine [<a href="#rid34">34</a>]. Treatment of methemoglobinemia with <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> (1 mg/kg IV) provides a prompt therapeutic effect, but repeat treatment may be required. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p class="headingAnchor" id="H578646532"><span class="h2">Infiltration</span><span class="headingEndMark"> — </span>Subcutaneous and tissue infiltration of LA is discussed separately  (<a class="graphic graphic_table graphicRef56799" href="/z/d/graphic/56799.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Methods to decrease injection pain'</a>.)</p><p class="headingAnchor" id="H1674299752"><span class="h2">Topical anesthetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin </strong>–<strong> </strong>Topical anesthetics on the skin are primarily used in children, and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">"Clinical use of topical anesthetics in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucous membranes </strong>–<strong> </strong>A number of preparations of LAs are available for topical anesthesia of the upper airway (ie, oropharynx and vocal cords), the trachea, and nasal passages. For anesthesia, topical anesthesia is most commonly used for awake laryngoscopy and intubation. LAs are available as ointments, gels, and solutions for nebulization, spray, and direct application.</p><p></p><p class="bulletIndent1">Available preparations that are used in anesthesia include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lidocaine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">Lidocaine</a> is available in a number of topical preparations, including 2% and 4% solutions, 2% and 4% gels, and 5% ointment, in addition to creams and patches that are used outside of anesthesia. When applied to mucous membranes, lidocaine provides onset of anesthesia within several minutes, and a variable duration of action of at least 30 minutes [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2">Maximal dosing limits for topical <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> should be followed (4.5 mg/kg, not to exceed 300 mg per dose), as LA systemic toxicity (LAST) can rarely occur, especially when the drug is applied to mucosal membranes in repeated or high doses. Lidocaine used for oropharyngeal anesthesia is absorbed through mucous membranes, and from the gastrointestinal tract when swallowed. There are multiple case reports of seizures and cardiac arrest with high doses of oral viscous lidocaine in adults and children. (See  <a class="medical medical_review" href="/z/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity", section on 'Routes of local anesthetic administration'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benzocaine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">Benzocaine</a> is a rapidly acting LA compound without an amine that can be protonated (therefore it is obligatorily uncharged) at physiologic pH. Its actions and kinetics are ideally suited for topical anesthesia of mucous membranes. (See <a class="local">'Speed of onset'</a> above and <a class="local">'Mechanism of action of local anesthetics'</a> above.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">Benzocaine</a> is available as a gel, liquid, ointment, and spray. The 20% spray is most commonly used for airway anesthesia. The dose of benzocaine spray administered is difficult to determine; the recommended maximum dose is 200 mg, which is delivered after a brief administration. Benzocaine is absorbed rapidly, especially if mucosa is not intact. Benzocaine administered for endoscopy has been associated with severe degrees of methemoglobinemia. For this reason, many institutions have replaced benzocaine with <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> for topical anesthesia [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cocaine</strong> – <a class="drug drug_general" data-topicid="10133" href="/z/d/drug information/10133.html" rel="external">Topical cocaine</a> is unique in its ability to provide both topical anesthesia and vasoconstriction, which is particularly advantageous when used for procedures on highly vascularized mucosae in the nose, mouth, and throat. Cocaine is available as a 4 percent solution, and provides rapid onset of action and duration of action of 30 to 60 minutes. Given its abuse potential, cocaine has largely been replaced by combinations of other LAs with vasoconstrictors such as tolazoline, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, or <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cornea and conjunctiva </strong>–<strong> </strong>Topical local anesthesia may be used for eye surgery. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/94538.html" rel="external">"Anesthesia for elective eye surgery", section on 'Topical anesthesia'</a>.)</p><p></p><p class="headingAnchor" id="H3306871750"><span class="h2">Systemic local anesthetic administration</span><span class="headingEndMark"> — </span>Unique among LAs, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> may be administered intravenously, as a bolus or infusion, for a variety of indications. Most clinicians will be familiar with the use of lidocaine for life threatening ventricular arrhythmias. Intravenous lidocaine may be administered to reduce the pain associated with injection of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>, and as an adjunct during induction of anesthesia, to blunt the sympathetic response to airway manipulation. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Lidocaine'</a>.)</p><p><a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">Lidocaine</a> has also been used as an intraoperative and postoperative intravenous infusion to improve analgesia following a variety of surgical procedures. (See  <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">"Nonopioid pharmacotherapy for acute pain in adults", section on 'Intravenous lidocaine'</a>.)</p><p class="headingAnchor" id="H405349935"><span class="h1">SUSTAINED RELEASE BUPIVACAINE</span></p><p class="headingAnchor" id="H1552961056"><span class="h2">Liposomal bupivacaine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> is a sustained-release formulation that consists of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> in an aqueous core encased in multiple phospholipid bilayers [<a href="#rid38">38</a>]. The liposomes are suspended in <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, with a pH of 5.8 to 7.4, and are available in a 20 mL single-use vial, with a bupivacaine concentration of 1.3%. The maximal allowable dose of liposomal bupivacaine is 266 mg by tissue infiltration (ie, one 20 mL vial) and 133 mg for interscalene block. For children 6 to 17 years old the recommended dose for infiltration is up to 4 mg/kg, maximum 266 mg. Liposomal bupivacaine should only be administered as a single dose.</p><p></p><p>When <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> is injected subcutaneously, the maximum plasma concentration is dose dependent [<a href="#rid39">39</a>]. The plasma concentration of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> exhibits an initial peak within one hour after administration, related to a small amount of extra-liposomal bupivacaine in the preparation, followed by a second peak 10 to 36 hours later. The maximal concentration, time to maximal concentration, and duration of detectable plasma bupivacaine vary widely depending on the injection site [<a href="#rid40">40-42</a>]. At a dose of 266 mg liposomal bupivacaine, plasma bupivacaine can be detectable as long as 72 hours after injection [<a href="#rid39">39</a>].</p><p>To avoid altering the release of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>, the manufacturer's recommendations for infiltration should be followed [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> may be diluted with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">Lactated Ringer</a>'s solution up to 1:14 by volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> should not be mixed with other LAs, except for aqueous <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> may be mixed in the same syringe as aqueous <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> or administered immediately after a dose of aqueous bupivacaine as long as the bupivacaine dose is ≤50 percent of the liposomal bupivacaine dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> should be administered no sooner than 20 minutes after injection of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, to avoid immediate release of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> from the liposome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid additional use of local anesthetics within 96 hours following administration of <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a>. </p><p></p><p><a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">Liposomal bupivacaine</a> is approved by the US Food and Drug Administration (FDA) for local infiltration at the surgical site for patients ≥6 years of age, and it is used by surgeons for tissue infiltration prior to wound closure (eg, for periarticular infiltration after joint arthroplasty). It is also approved for field block (including transversus abdominis plane [TAP] block, which is defined as a field block by the FDA), interscalene block, adductor canal block, and popliteal block, all for postsurgical pain [<a href="#rid44">44</a>]. The drug manufacturer does not recommend the use of liposomal bupivacaine for other regional, epidural or intrathecal blocks [<a href="#rid43">43</a>].</p><p>Limited evidence suggests that <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> injected for local infiltration may improve postoperative analgesia compared with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, but liposomal bupivacaine is not clearly superior to aqueous <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> [<a href="#rid45">45-48</a>]. Similarly, whereas the use of liposomal bupivacaine for peripheral nerve block is increasingly reported, benefits compared with aqueous bupivacaine have not been clearly demonstrated [<a href="#rid49">49-52</a>] and existing studies have not compared equivalent milligram doses of the two drugs. Liposomal bupivacaine is significantly more expensive than aqueous bupivacaine.</p><p class="bulletIndent1"><span class="glyph">●</span>A 2021 meta-analysis of nine randomized trials that compared <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> with non-liposomal <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> for peripheral nerve blocks found that liposomal bupivacaine improved the area under the curve of pain scores from 24 to 72 hours by a clinically unimportant amount (1.0 cm/hour [95% CI 0.5-1.6], on a scale of 0 to 10 cm) [<a href="#rid49">49</a>]. Opioid consumption, time to first analgesic request, and opioid-related side effects were similar in patients who received either drug.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another 2021 meta-analysis of 23 randomized trials that compared <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> with non-liposomal <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> for local anesthesia, infiltration, or peripheral nerve block found that liposomal bupivacaine resulted in statistically significant but clinically irrelevant reductions in postoperative pain scores and opioid consumption at 24 hours [<a href="#rid50">50</a>]. The mean difference in pain scores was -0.37 (95% CI -0.56 to -0.19) on a numerical rating scale of 0 to 10; mean 24-hour <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> consumption was reduced by 0.85 mg (96% CI 0.82-0.89 mg), favoring liposomal bupivacaine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review of 76 randomized trials concluded that there was no clear evidence in support of the use of <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> rather than non-liposomal <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> for either peripheral nerve block or local infiltration [<a href="#rid51">51</a>].</p><p></p><p>The cardiac safety profile for <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> is similar to that of aqueous <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity", section on 'Amide local anesthetics'</a>.)</p><p class="headingAnchor" id="H2530824213"><span class="h2">Novel formulations</span><span class="headingEndMark"> — </span>Several formulations of extended-release <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>. Clinical experience with each of them is limited, and further study is required before recommending routine use.</p><p class="bulletIndent1"><span class="glyph">●</span>In 2021 a novel sustained-release formulation of <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> (Posimir) was FDA approved for injection into the subacromial space under direct arthroscopic visualization [<a href="#rid54">54</a>]. The dose is 660 mg (5 mL vial) and unlike <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a>, it should not be diluted or mixed with other drugs or solutions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> collagen implant is now available for postoperative analgesia following open inguinal hernia repair. The recommended dose is 300 mg (three 100 mg implants placed in the wound prior to closure) [<a href="#rid55">55</a>]. Like Posimir, FDA approval was given based on clinical trials demonstrating improved post-operative analgesia versus placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2021 an extended release combination <a class="drug drug_general" data-topicid="131644" href="/z/d/drug information/131644.html" rel="external">bupivacaine-meloxicam</a> (Zynrelef) was FDA approved and is available for topical application into the wound for foot and ankle, small to medium open abdominal, and lower extremity joint arthroplasty surgery [<a href="#rid56">56</a>]. The mixed solution is applied to tissues below the level of the skin, after final wound irrigation. The maximum recommended dose for TKA is 14 mL (<a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> 400 mg/<a class="drug drug_general" data-topicid="10295" href="/z/d/drug information/10295.html" rel="external">meloxicam</a> 12 mg). Zynrelef carries an FDA boxed warning for cardiovascular and gastrointestinal toxicities related to meloxicam, which is a nonsteroidal anti-inflammatory drug (NSAID).</p><p></p><p class="headingAnchor" id="H1279685632"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129632.html" rel="external">"Society guideline links: Local and regional anesthesia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/129826.html" rel="external">"Society guideline links: Local anesthetic systemic toxicity"</a>.)</p><p class="headingAnchor" id="H4283198932"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of local anesthetics</strong> – The chemical structure of commonly used local anesthetics (LAs) consists of an aromatic ring and a tertiary amine, linked by either a carboxylic ester or an amide bond. The amino ester group of LAs includes <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a>, <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a>, and procaine. The amino amide group includes <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>, <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a>, <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a>, and outside the United States, levobupivacaine. (See <a class="local">'Basic structure/classes'</a> above.)</p><p></p><p class="bulletIndent1">Metabolism of an LA depends on its chemical structure. Ester LAs are hydrolyzed by plasma cholinesterase, and amide LAs are metabolized via N-dealkylation by hepatic enzymes. (See <a class="local">'Metabolism of local anesthetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacodynamics</strong> – LA pharmacodynamics are determined by the physicochemical properties of the drug, and the specific way in which the drug is used  (<a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef108422" href="/z/d/graphic/108422.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potency of an LA is strongly associated with lipid solubility.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The speed of onset of LA conduction block associates with the physicochemical properties of the specific drug, the concentration of the solution, and the site of injection. In general, the time to onset increases with increasing lipid solubility, and more rapid onset is expected when the solution contains a greater fraction of nonionized molecules. (See <a class="local">'Speed of onset'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Onset of block is almost immediate with subcutaneous or tissue infiltration and with intrathecal injection. Onset is delayed if LA must diffuse through tissue to reach the target nerves.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>LA solutions may be alkalinized to speed onset, by increasing the fraction of un-ionized LA molecules.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Duration of action of LA is determined in part by lipophilicity, but varies widely by site of injection and other drug characteristics. (See <a class="local">'Duration of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum levels</strong> – Serum levels of LA can be the result of systemic absorption from block sites, or inadvertent intravascular injection. Maximum allowable doses can be used as a starting point for deciding on a dose, but are not evidence based. (See <a class="local">'Maximum allowable doses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal anesthesia</strong> – For spinal anesthesia, the LA must be chosen to achieve the required spinal level and duration of anesthesia  (<a class="graphic graphic_table graphicRef108422" href="/z/d/graphic/108422.html" rel="external">table 2</a>). The most important determinants of the extent of sensory block are the baricity and (with hypobaric and hyperbaric solutions) the patient's position after injection of the anesthetic solution. (See <a class="local">'Spinal anesthesia'</a> above.)</p><p></p><p class="bulletIndent1">Transient neurologic symptoms (TNS) have been associated with the use of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> for spinal anesthesia, particularly for patients undergoing surgery in the lithotomy position. Most other LAs are associated with a lower risk of TNS. (See <a class="local">'Neurotoxicity of local anesthetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidural anesthesia</strong> – For epidural anesthesia, the volume and total LA dose are the two most important drug related factors that influence the dermatomal extent and density of block  (<a class="graphic graphic_table graphicRef113031" href="/z/d/graphic/113031.html" rel="external">table 4</a>). (See <a class="local">'Epidural anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral nerve blocks</strong> – For peripheral nerve block, the LA and its volume and concentration are chosen according to the goal of the block (ie, surgical anesthesia and/or postoperative analgesia), degree of motor block, toxicity, and the desired duration of the block  (<a class="graphic graphic_table graphicRef93203" href="/z/d/graphic/93203.html" rel="external">table 1</a>). (See <a class="local">'Peripheral nerve block'</a> above.)</p><p></p><p class="bulletIndent1">Benefits of <a class="drug drug_general" data-topicid="17057" href="/z/d/drug information/17057.html" rel="external">liposomal bupivacaine</a> over aqueous <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> have not been clearly demonstrated. (See <a class="local">'Sustained release bupivacaine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous regional anesthesia</strong> – For intravenous regional anesthesia, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> is the LA used most commonly in the United States, whereas <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">prilocaine</a> is used elsewhere. (See <a class="local">'Intravenous regional anesthesia'</a> above and  <a class="medical medical_review" href="/z/d/html/100069.html" rel="external">"Upper extremity nerve blocks: Techniques", section on 'Intravenous regional anesthesia (Bier block)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical anesthesia</strong> – Topical anesthesia is most commonly used to anesthetize the upper airway, nasal passages, and trachea, for awake laryngoscopy and intubation. Multiple preparations of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> are available for topical anesthesia. LA toxicity can occur with the use of topical LA, especially when the drug is applied in repeated or high doses. (See <a class="local">'Topical anesthetics'</a> above.)</p><p></p><p class="headingAnchor" id="H2121954524"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John Butterworth, IV, MD (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Butterworth JF 4th, Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology 1990; 72:711.</a></li><li><a class="nounderline abstract_t">Docherty RJ, Farmer CE. The pharmacology of voltage-gated sodium channels in sensory neurones. Handb Exp Pharmacol 2009; :519.</a></li><li><a class="nounderline abstract_t">Taboada Muñiz M, Rodríguez J, Bermúdez M, et al. Low volume and high concentration of local anesthetic is more efficacious than high volume and low concentration in Labat's sciatic nerve block: a prospective, randomized comparison. Anesth Analg 2008; 107:2085.</a></li><li><a class="nounderline abstract_t">Soeding PE, Sha S, Royse CE, et al. A randomized trial of ultrasound-guided brachial plexus anaesthesia in upper limb surgery. Anaesth Intensive Care 2005; 33:719.</a></li><li><a class="nounderline abstract_t">DiFazio CA, Carron H, Grosslight KR, et al. Comparison of pH-adjusted lidocaine solutions for epidural anesthesia. Anesth Analg 1986; 65:760.</a></li><li><a class="nounderline abstract_t">Frank SG, Lalonde DH. How acidic is the lidocaine we are injecting, and how much bicarbonate should we add? Can J Plast Surg 2012; 20:71.</a></li><li class="breakAll">Cousins MJ. Cousins and Bridenbaugh Neural Blockade in Clinical Anesthesia and Pain Medicine, Lippincott Williams and Wilkins, 2012.</li><li class="breakAll">Raymond SA, Gissen AJ. Mechanisms of differential nerve block. In: Local anesthetics: Handbook of experimental pharmacology, Strichartz GR (Ed), Springer Berlin Heidelberg, 1987. Vol 81, p.95.</li><li><a class="nounderline abstract_t">Raymond SA, Steffensen SC, Gugino LD, Strichartz GR. The role of length of nerve exposed to local anesthetics in impulse blocking action. Anesth Analg 1989; 68:563.</a></li><li class="breakAll">Tasaki I. Nervous transmission, Thomas, Springfield, IL 1953.</li><li><a class="nounderline abstract_t">Gokin AP, Philip B, Strichartz GR. Preferential block of small myelinated sensory and motor fibers by lidocaine: in vivo electrophysiology in the rat sciatic nerve. Anesthesiology 2001; 95:1441.</a></li><li><a class="nounderline abstract_t">Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med 2010; 35:181.</a></li><li><a class="nounderline abstract_t">Kuhnert BR, Philipson EH, Pimental R, Kuhnert PM. A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase. Anesthesiology 1982; 56:477.</a></li><li><a class="nounderline abstract_t">SHNIDER SM. SERUM CHLONESTERASE ACTIVITY DURING PREGNANCY, LABOR AND THE PUERPERIUM. Anesthesiology 1965; 26:335.</a></li><li><a class="nounderline abstract_t">Kuhnert BR, Kuhnert PM, Philipson EH, et al. The half-life of 2-chloroprocaine. Anesth Analg 1986; 65:273.</a></li><li><a class="nounderline abstract_t">Werdehausen R, Fazeli S, Braun S, et al. Apoptosis induction by different local anaesthetics in a neuroblastoma cell line. Br J Anaesth 2009; 103:711.</a></li><li><a class="nounderline abstract_t">Zaric D, Pace NL. Transient neurologic symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics. Cochrane Database Syst Rev 2009; :CD003006.</a></li><li><a class="nounderline abstract_t">Hampl KF, Schneider MC, Ummenhofer W, Drewe J. Transient neurologic symptoms after spinal anesthesia. Anesth Analg 1995; 81:1148.</a></li><li><a class="nounderline abstract_t">Pollock JE, Neal JM, Stephenson CA, Wiley CE. Prospective study of the incidence of transient radicular irritation in patients undergoing spinal anesthesia. Anesthesiology 1996; 84:1361.</a></li><li><a class="nounderline abstract_t">Freedman JM, Li DK, Drasner K, et al. Transient neurologic symptoms after spinal anesthesia: an epidemiologic study of 1,863 patients. Anesthesiology 1998; 89:633.</a></li><li><a class="nounderline abstract_t">Liu SS, McDonald SB. Current issues in spinal anesthesia. Anesthesiology 2001; 94:888.</a></li><li><a class="nounderline abstract_t">Rigler ML, Drasner K, Krejcie TC, et al. Cauda equina syndrome after continuous spinal anesthesia. Anesth Analg 1991; 72:275.</a></li><li><a class="nounderline abstract_t">Reisner LS, Hochman BN, Plumer MH. Persistent neurologic deficit and adhesive arachnoiditis following intrathecal 2-chloroprocaine injection. Anesth Analg 1980; 59:452.</a></li><li><a class="nounderline abstract_t">Ravindran RS, Bond VK, Tasch MD, et al. Prolonged neural blockade following regional analgesia with 2-chloroprocaine. Anesth Analg 1980; 59:447.</a></li><li><a class="nounderline abstract_t">Moore DC, Spierdijk J, vanKleef JD, et al. Chloroprocaine neurotoxicity: four additional cases. Anesth Analg 1982; 61:155.</a></li><li><a class="nounderline abstract_t">Salmela L, Aromaa U. Transient radicular irritation after spinal anesthesia induced with hyperbaric solutions of cerebrospinal fluid-diluted lidocaine 50 mg/ml or mepivacaine 40 mg/ml or bupivacaine 5 mg/ml. Acta Anaesthesiol Scand 1998; 42:765.</a></li><li><a class="nounderline abstract_t">Hiller A, Rosenberg PH. Transient neurological symptoms after spinal anaesthesia with 4% mepivacaine and 0.5% bupivacaine. Br J Anaesth 1997; 79:301.</a></li><li><a class="nounderline abstract_t">YaDeau JT, Liguori GA, Zayas VM. The incidence of transient neurologic symptoms after spinal anesthesia with mepivacaine. Anesth Analg 2005; 101:661.</a></li><li><a class="nounderline abstract_t">Liguori GA, Zayas VM, Chisholm MF. Transient neurologic symptoms after spinal anesthesia with mepivacaine and lidocaine. Anesthesiology 1998; 88:619.</a></li><li><a class="nounderline abstract_t">Salazar F, Bogdanovich A, Adalia R, et al. Transient neurologic symptoms after spinal anaesthesia using isobaric 2% mepivacaine and isobaric 2% lidocaine. Acta Anaesthesiol Scand 2001; 45:240.</a></li><li><a class="nounderline abstract_t">Gadsden J, Hadzic A, Gandhi K, et al. The effect of mixing 1.5% mepivacaine and 0.5% bupivacaine on duration of analgesia and latency of block onset in ultrasound-guided interscalene block. Anesth Analg 2011; 112:471.</a></li><li><a class="nounderline abstract_t">Laur JJ, Bayman EO, Foldes PJ, Rosenquist RW. Triple-blind randomized clinical trial of time until sensory change using 1.5% mepivacaine with epinephrine, 0.5% bupivacaine, or an equal mixture of both for infraclavicular block. Reg Anesth Pain Med 2012; 37:28.</a></li><li><a class="nounderline abstract_t">Bader AM, Concepcion M, Hurley RJ, Arthur GR. Comparison of lidocaine and prilocaine for intravenous regional anesthesia. Anesthesiology 1988; 69:409.</a></li><li><a class="nounderline abstract_t">Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg 2009; 108:837.</a></li><li class="breakAll">Covino BG, Vasallo HG. Local anesthetics mechanisms of action and clinical use, Grune &amp; Stratton, New York 1976. p.90.</li><li class="breakAll">US Food and Drug Administration. 2011 Drug Safety Communications. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm285549.htm (Accessed on April 19, 2019).</li><li class="breakAll">FDA Drug Safety Communication: FDA continues to receive reports of a rare, but serious and potentially fatal adverse effect with the use of benzocaine sprays for medical procedures. Available at: https://www.fda.gov/drugs/drugsafety/ucm250040.htm.</li><li><a class="nounderline abstract_t">Grant GJ, Barenholz Y, Bolotin EM, et al. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 2004; 101:133.</a></li><li><a class="nounderline abstract_t">Hu D, Onel E, Singla N, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig 2013; 33:109.</a></li><li><a class="nounderline abstract_t">Richard BM, Ott LR, Haan D, et al. The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs. Expert Opin Investig Drugs 2011; 20:1327.</a></li><li><a class="nounderline abstract_t">Davidson EM, Barenholz Y, Cohen R, et al. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg 2010; 110:1018.</a></li><li><a class="nounderline abstract_t">Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee 2012; 19:530.</a></li><li class="breakAll">Dosing &amp; administration. EXPAREL. https://www.exparel.com/hcp/about-exparel/dosing-and-administration#:~:text=Avoid%20additional%20use%20of%20anesthetics%20within%2096%20hours%20following%20administration%20of%20EXPAREL (Accessed on October 06, 2023).</li><li class="breakAll">FDA drug label and prescribing information for EXPAREL liposomal bupivacaine. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022496s044lbl.pdf (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Hamilton TW, Athanassoglou V, Mellon S, et al. Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. Cochrane Database Syst Rev 2017; 2:CD011419.</a></li><li><a class="nounderline abstract_t">Sandhu HK, Miller CC 3rd, Tanaka A, et al. Effectiveness of Standard Local Anesthetic Bupivacaine and Liposomal Bupivacaine for Postoperative Pain Control in Patients Undergoing Truncal Incisions: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e210753.</a></li><li><a class="nounderline abstract_t">Abdallah FW, Hussain N, Brull R. Analgesic efficacy of liposomal bupivacaine for surgical site infiltration: a single-outcome meta-analysis (the best we could do). Reg Anesth Pain Med 2021; 46:291.</a></li><li><a class="nounderline abstract_t">Fidkowski CW, Choksi N, Alsaden MR. A randomized-controlled trial comparing liposomal bupivacaine, plain bupivacaine, and the mixture of liposomal bupivacaine and plain bupivacaine in transversus abdominus plane block for postoperative analgesia for open abdominal hysterectomies. Can J Anaesth 2021; 68:773.</a></li><li><a class="nounderline abstract_t">Hussain N, Brull R, Sheehy B, et al. Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia. Anesthesiology 2021; 134:147.</a></li><li><a class="nounderline abstract_t">Dinges HC, Wiesmann T, Otremba B, et al. The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis. Reg Anesth Pain Med 2021; 46:490.</a></li><li><a class="nounderline abstract_t">Ilfeld BM, Eisenach JC, Gabriel RA. Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Anesthesiology 2021; 134:283.</a></li><li><a class="nounderline abstract_t">Elmer DA, Coleman JR, Renwick CM, et al. Comparing bupivacaine alone to liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty: a randomized, non-inferiority trial. Reg Anesth Pain Med 2023; 48:1.</a></li><li><a class="nounderline abstract_t">Bergese SD, Onel E, Morren M, Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med 2012; 37:145.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204803s000lbl.pdf.</li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2020/209511s000lbl.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s005lbl.pdf.</li></ol></div><div id="topicVersionRevision">Topic 14929 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2157353" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular mechanisms of local anesthesia: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655117" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The pharmacology of voltage-gated sodium channels in sensory neurones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020163" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Low volume and high concentration of local anesthetic is more efficacious than high volume and low concentration in Labat's sciatic nerve block: a prospective, randomized comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16398375" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A randomized trial of ultrasound-guided brachial plexus anaesthesia in upper limb surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717616" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of pH-adjusted lidocaine solutions for epidural anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730153" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : How acidic is the lidocaine we are injecting, and how much bicarbonate should we add?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730153" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : How acidic is the lidocaine we are injecting, and how much bicarbonate should we add?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730153" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How acidic is the lidocaine we are injecting, and how much bicarbonate should we add?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785778" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of length of nerve exposed to local anesthetics in impulse blocking action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785778" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The role of length of nerve exposed to local anesthetics in impulse blocking action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11748404" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Preferential block of small myelinated sensory and motor fibers by lidocaine: in vivo electrophysiology in the rat sciatic nerve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20301824" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081736" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14289955" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : SERUM CHLONESTERASE ACTIVITY DURING PREGNANCY, LABOR AND THE PUERPERIUM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954093" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The half-life of 2-chloroprocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19700777" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Apoptosis induction by different local anaesthetics in a neuroblastoma cell line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370578" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transient neurologic symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486096" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transient neurologic symptoms after spinal anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8669677" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prospective study of the incidence of transient radicular irritation in patients undergoing spinal anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743399" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Transient neurologic symptoms after spinal anesthesia: an epidemiologic study of 1,863 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11388543" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Current issues in spinal anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994754" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cauda equina syndrome after continuous spinal anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7189987" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Persistent neurologic deficit and adhesive arachnoiditis following intrathecal 2-chloroprocaine injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7189986" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prolonged neural blockade following regional analgesia with 2-chloroprocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7198876" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chloroprocaine neurotoxicity: four additional cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9698950" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Transient radicular irritation after spinal anesthesia induced with hyperbaric solutions of cerebrospinal fluid-diluted lidocaine 50 mg/ml or mepivacaine 40 mg/ml or bupivacaine 5 mg/ml.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389845" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Transient neurological symptoms after spinal anaesthesia with 4% mepivacaine and 0.5% bupivacaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115971" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The incidence of transient neurologic symptoms after spinal anesthesia with mepivacaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9523803" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transient neurologic symptoms after spinal anesthesia with mepivacaine and lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167171" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transient neurologic symptoms after spinal anaesthesia using isobaric 2% mepivacaine and isobaric 2% lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21156983" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of mixing 1.5% mepivacaine and 0.5% bupivacaine on duration of analgesia and latency of block onset in ultrasound-guided interscalene block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157740" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Triple-blind randomized clinical trial of time until sensory change using 1.5% mepivacaine with epinephrine, 0.5% bupivacaine, or an equal mixture of both for infraclavicular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3415022" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of lidocaine and prilocaine for intravenous regional anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224791" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Methemoglobinemia related to local anesthetics: a summary of 242 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224791" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Methemoglobinemia related to local anesthetics: a summary of 242 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224791" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Methemoglobinemia related to local anesthetics: a summary of 242 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224791" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Methemoglobinemia related to local anesthetics: a summary of 242 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220782" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229686" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21867476" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357145" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285545" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285545" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285545" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28146271" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33724391" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness of Standard Local Anesthetic Bupivacaine and Liposomal Bupivacaine for Postoperative Pain Control in Patients Undergoing Truncal Incisions: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33547090" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Analgesic efficacy of liposomal bupivacaine for surgical site infiltration: a single-outcome meta-analysis (the best we could do).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33432496" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A randomized-controlled trial comparing liposomal bupivacaine, plain bupivacaine, and the mixture of liposomal bupivacaine and plain bupivacaine in transversus abdominus plane block for postoperative analgesia for open abdominal hysterectomies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33372953" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33837139" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33372949" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36261261" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparing bupivacaine alone to liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty: a randomized, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266897" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
